# A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

> **NCT01050582** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 244 (actual)

## Conditions studied

- Schizophrenia
- Bipolar Disorder
- Autistic Disorder
- Conduct and Other Disruptive Behavior Disorders

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Other atypical antipsychotic drugs

## Key facts

- **NCT ID:** NCT01050582
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2012-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01050582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01050582, "A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01050582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*